IMPLANON SUMMARY
IMPLANON™ (etonogestrel implant) is an off-white, non-biodegradable, etonogestrel-containing single sterile rod implant for subdermal use. The implant is 4 cm in length with a diameter of 2 mm (see Figure 1). Each IMPLANON™ rod consists of an ethylene vinylacetate (EVA) copolymer core, containing 68 mg of the synthetic progestin etonogestrel (ENG), surrounded by an EVA copolymer skin. The release rate is 60-70 µg/day in week 5-6 and decreases to approximately 35-45 µg/day at the end of the first year, to approximately 30-40 µg/day at the end of the second year, and then to approximately 25-30 µg/day at the end of the third year. IMPLANON™ is a progestin-only contraceptive and does not contain estrogen. IMPLANON™ does not contain latex and is not radio-opaque.
IMPLANON™ (etonogestrel implant) is indicated for women for the prevention of pregnancy. IMPLANON™ is a long-acting (up to 3 years), reversible, contraceptive method. IMPLANON™ must be removed by the end of the third year and may be replaced by a new IMPLANON™ at the time of removal, if continued contraceptive protection is desired.
|
IMPLANON NEWS HIGHLIGHTS
Media Articles Related to Implanon (Etonogestrel Subcutaneous)
Leavitt's Actions On HHS Draft Rule Leave Possibility That It Will Be Used To Refuse Contraception, Opinion Piece Says
Source: Sexual Health / STDs News From Medical News Today [2008.09.03]
Governor Palin Is Pro-Life, Pro-contraception, And Pro-competition In Health Care
Source: Abortion News From Medical News Today [2008.08.30]
New Concepts In Contraception
Source: Sexual Health / STDs News From Medical News Today [2008.08.28]
'Extended Cycle' Contraception Garners More Interest
Source: MedicineNet Birth Control Specialty [2008.08.25]
Male Contraception: Progress Slow but Steady
Source: MedicineNet Vasectomy Specialty [2008.04.14]
Published Studies Related to Implanon (Etonogestrel Subcutaneous)
7alpha-methyl-19-nortestosterone (MENT) vs testosterone in combination with etonogestrel implants for spermatogenic suppression in healthy men. [2007.09]
Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of a contraceptive vaginal ring and an oral contraceptive. [2006.01]
A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. [2006.01]
A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive. [2006.01]
Effect on insulin sensitivity of Implanon vs. GnRH agonist in women with endometriosis. [2005.12]
Clinical Trials Related to Implanon (Etonogestrel Subcutaneous)
Pharmacokinetics of Implanon in Obese Women [Recruiting]
A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate [Recruiting]
Hormonal Contraception in Healthy Young Men [Completed]
Hormonal Contraception & Vaginal Health [Recruiting]
Comparison of Serum Contraceptive Hormone Levels Between Normal Weight and Obese Users of the NuvaRing® [Recruiting]
|
